Athira Pharma, Inc.
NASDAQ: ATHA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark J. Litton
- Employees
- 26
- Headquarters
- Bothell, United States
- IPO year
- 2020
- Market cap
- $26.6M
- Website
- https://www.athira.com
Loading ATHA…
Loading profile data…Frequently asked questions about ATHA
What does Athira Pharma, Inc. (ATHA) do?
Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable...
Where does ATHA trade?
Athira Pharma, Inc. (ATHA) trades on the NASDAQ Global Select.
What sector is ATHA in?
Athira Pharma, Inc. (ATHA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Athira Pharma, Inc.?
Mark J. Litton is the chief executive officer of Athira Pharma, Inc. (ATHA).
Where is Athira Pharma, Inc. headquartered?
Athira Pharma, Inc. is headquartered in United States.
Does ATHA pay a dividend?
Athira Pharma, Inc. (ATHA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATHA go public?
Athira Pharma, Inc. (ATHA) completed its initial public offering in 2020.